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ABSTRACT 
 
Previous studies have associated stuttering with increased levels of self-stigma. Prior 
research has shown that high levels of self-stigma may relate to increased medication usage. 
Therefore, in the present study, the authors sought to determine an association between levels of 
self-stigma and medication usage among adults who stutter. Results suggest that although there 
is not a significant difference for lifetime medication use between AWS versus AWNS, the self-
imposed stigma by AWS could predict the likelihood of medication use.  Findings provide 
insight into additional pharmacological factors to consider during clinical intervention, and 
highlight the importance of stigmatized beliefs when addressing the needs of a client who 
stutters. 
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CHAPTER I: INTRODUCTION 
 
Stuttering is a multifactorial communication disorder that affects approximately 1% of 
the adult population and characterized by frequent sound prolongations, repetitions, and pauses 
during the production of speech (e.g., Conture, 2001; Guitar, 2013; Yairi & Seery, 2011). Along 
with these atypical speech disturbances, adults who stutter (AWS) often report negative 
cognitive and affective characteristics, such as overall lower quality of life (e.g., Craig, 
Blumgart, & Tran, 2009; de Sonneville-Koedoot, Bouwmans, Franken, & Stolk, 2011), social 
anxiety (e.g., Iverach et al., 2009) and depression (e.g., Iverach et al., 2010). As described by 
Boyle (2015), one overarching characteristic – self-stigma – strongly correlates with these three 
negative psychosocial variables within AWS, and Boyle (2013) provided evidence that stuttering 
should be considered a highly stigmatized condition based on well-established models of 
stigmatization within the field of mental health (Corrigan, Rafacz, & Rüsch, 2011).  Highly 
stigmatized conditions (e.g., anxiety disorders: Alonso et al., 2008; depression: Montesinos et al., 
2012) have also been found to correlate with increased substance use (e.g., Lai, Cleary, 
Sitharthan, & Hunt, 2015). Given the stigmatized nature of persistent stuttering, it would be 
expected that increased substance use may also be present in AWS compared to adults who do 
not stutter (AWNS).   
There have been many investigations of medication use within stigmatized clinical 
populations within the field of psychology; however, the relationship between medication use 
and stuttering has limited to one study by Iverach et al. (2010).  Iverach et al. compared the 
likelihood of 92 AWS clients to meet the diagnostic criteria for substance abuse disorder, as 
defined by the DSM-IV (2000), compared to 920 age-matched controls from a national health 
database.  Contrary to expectations, data from this study indicate a reduced likelihood of 
substance use disorders in AWS relative to AWNS.  However, at least two critical limitations 
warrant caution when generalizing these data to characterize patterns of medication use in the 
larger AWS population.  First, AWS included in the study were recruited from a waitlist for 
clinical services.  As acknowledged by the authors, recruitment of AWS individuals who had 
actively sought treatment may have been more willing to enter performance-based situations 
involving potential scrutiny by others.  If this is the case, the AWS sampled may represent (a) a 
cohort of AWS with lower levels self-stigma, and by extension, (b) a cohort with lower 
likelihood of self-medication.  Second, the DSM-IV criteria used in the study – typically used to 
diagnose substance abuse disorder - may have been too stringent to assess subclinical patterns of 
medication use in AWS who do not exhibit physiological dependence or critical indicators of 
clinical impairment at the time the study was completed, such as withdrawal, tolerance, and 
drug-seeking behaviors. 
Based on these limitations, the present study investigates patterns of medication use in 
AWS and AWNS within cohorts not restricted to clinical waitlists, and assessed irrespective of 
DSM-IV criteria.  To further explore the relationship between self-stigma and medication use in 
AWS, perceived self-stigma of AWS respondents will be assessed using an established, 
psychometrically-valid questionnaire specific to the stuttering population. It is predicted that 
medication use, rather than medication abuse, will be greater in AWS relative to AWNS. It is 
further predicted that heightened stigmatization reported by AWS may result in increased 
medication use.  Findings will provide much needed data regarding potential risk factors that 
may further diminish psychological and physical health in AWS.  
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Self-stigma and stuttering 
Recent studies by Boyle (2013, 2015) have investigated the increased level of public 
stigma and self-stigma reported by AWS.  According to Corrigan et al. (2011), the progression of 
self-stigma is composed of four stages: awareness, agreement, application, and harm:  (1) the 
person is made aware that they are stigmatized by the public, (2) the person begins to agree with 
the stigmatizing attitudes of the public and stereotype others with the condition, (3) they apply 
the stigmatizing attitudes toward themselves personally, and (4) they experience psychological 
harm in the form of reduced well-being and societal participation. Heightened levels of self-
stigmatization may also affect the decision to initiate treatment. Corrigan, Larson, and Rüsch 
(2009) and Rüsch et al. (2009) discussed the “Why Try” effect that often co-occurs within 
stigmatized individuals in clinical settings, which suggested that high levels of self-
stigmatization results in the lack of empowerment to enhance service utilization, and reduced 
likelihood to initiate clinical services.  Robinson, Sareen, Cox, and Bolton (2011) examined 
individuals with anxiety disorders such as social phobia, and found that self-stigmatized 
populations are also at greater risk for self-medication (e.g., use of alcohol or prescription drugs).  
Importantly, Robinson et al. also found that these populations were at increased risk for 
developing long-term substance dependence.  Based on these data, populations with other 
stigmatized conditions such as stuttering may be particularly vulnerable to eventual substance 
abuse disorder if self-medication or elevated medication use are also present. 
 Boyle (2013, 2015) developed the Self-Stigma Scale of Stuttering (4S) that assessed a 
broad sample of AWS (n = 354) and their beliefs regarding stuttering, mental health, and overall 
quality of life. AWS completed a survey that included an assessment of self-stigma, anxiety, 
depression, and quality of life. Self-stigma was assessed using and adapted version of the Self-
Stigma of Mental Health questionnaire developed by Corrigan, Watson and Barr (2006).  
Anxiety was assessed using the Generalized Anxiety Disorder 7-item (GAD-7) (Spitzer, 
Kroenke, Williams, & Löwe, 2006). Depression was measured using the Patient Health 
Questionnaire (PHQ-9) (Kroenke, Spitzer, & Williams, 2001). A quality of life measure 
followed, assessed using the Quality of Life Enjoyment and Satisfaction Questionnaire – Short 
Form (Endicott, Nee, Harrison, & Blumenthal, 1993). Ratings of self-stigma shared a positive 
correlation with anxiety (r = .42) along with depression (r = .44), and a negative correlation with 
overall quality of life (r = -.40). Based on the heighted levels of self-stigma identified in many 
AWS, and the relationship between anxiety and self-medication reported by Robinson et al. 
(2011), increased substance use may also be prevalent within the adult stuttering population.  
 
Medication use in adults who stutter    
 Surprisingly, there has been little experimental effort put into investigating substance use 
in AWS. Despite the fact that there has been no approved medication by the FDA for treatment 
of stuttering (Maguire, Yeh, & Ito, 2012), a large-scale survey study by the National Stuttering 
Association (2009) found approximately one-third of AWS (n = 711) and one-quarter of parents 
of children who stutter (n = 164) had tried alternative methods of treatment, including 
prescription medication, with varying levels of success.  The reasons for potential medication use 
in fluency clients remain speculative and have received little empirical review.  In a study by 
Yairi and Carrico (1992) investigating a sample of 100 pediatricians and their views of 
stuttering, 96% disagree that medications would be beneficial to children who stutter.  However, 
this study also revealed that nearly four out of five pediatricians (79%) advocated a “wait-and- 
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see” approach, and over one-third (36%) reported that treatment, if sought, would be best  
provided by professionals other than speech-language pathologists.  Consistent with these 
numbers, an estimated one-third of AWS within the 2009 NSA survey had reported seeking 
services from a psychologist and/or psychiatrist to address fluency concerns, thereby increasing 
the likelihood of medication prescription.   
Even within the field of speech-language pathology, research indicate that many SLPs (a) 
express lack of competence when treating fluency clients (e.g., Cooper & Cooper, 1985; Kelly et 
al., 1997; Gabel, 2014), (b) believe that stuttering is psychological rather than biological in origin 
(Boyle, 2014), and (c) endorse the “stuttering stereotype,”  or the belief that AWS exhibit certain 
negative personality traits more so than AWNS, such as being nervous, tense, afraid, shy, and 
self-conscious (e.g., Guntupalli, Nanjundeswaran, Dayalu, & Kalinowski, 2012; MacKinnon, 
Hall, & MacIntyre, 2007; Woods & Williams, 1976).  The combination of SLPs’ limited 
knowledge of effective behavioral intervention, belief in psychological etiology of the disorder, 
and medication-conducive client profile may, at minimum, reduce the likelihood that SLPs 
would dissuade fluency clients from seeking or using medications.  In sum, inconsistent 
treatment recommendations and limited qualification of professionals throughout life may 
provide the ideal scenario for increased substance use in AWS.  Further, AWS report that they 
generally accept the negative stereotypes of the public and, when asked, tend to agree that 
individuals who stutter are more anxious, insecure, withdrawn, and fearful than AWNS (Lass et 
al., 1995; Logan & Willis, 2011).  This increased level of self-stigmatization in AWS may 
further exacerbate the proclivity towards self-medication within the adult stuttering population.  
 Only one study by Iverach et al. (2010) has examined substance use disorders in AWS. 
Iverach and colleagues hypothesized that AWS with increased rates of anxiety detailed in 
Iverach et al. (2009) may also exhibit heightened rates of mood disorders and substance use 
disorders similar to individuals with anxiety disorders who do not stutter (for review see, Bolton, 
Cox, Clara, & Sareen, 2006). Similar to Iverach et al. (2009), AWS participants were recruited 
from a waitlist across university stuttering treatment clinics in Australia and New Zealand who 
were seeking treatment for stuttering. The CIDI-Auto-2.1 (WHO, 1997), a standardized 
computer interview used to assess and diagnose mental health disorders according to DSM-IV 
(2000) criteria, was administered to respondents who were then asked to provide information via 
self-report.  Respondents provided symptomatic information and a relative time frame of 
symptomology (e.g., “Within the last two weeks, did you exhibit x symptom?” and “When did x 
symptom first appear?”).  Logistic regression analyses revealed that, as predicted, AWS were 
characterized by higher likelihood of mood disorders than the matched controls according the 
DSM-IV description. However, contrary to predictions, AWS were found no more likely to meet 
the criteria for medication or alcohol abuse than AWNS based on DSM-IV criteria.   
 
Limitations to Iverach et al. (2010) 
Findings from Iverach et al. (2010) were surprising given the reported co-occurrence 
between fluency disorders and anxiety disorders in AWS. Despite the increased anxiety reported 
by Iverach et al. (2009) in AWS relative to AWNS and the increased likelihood of AWS to meet 
criteria for social anxiety disorder (four-fold increased odds) or social phobia (16- to 34-fold 
increased odds), Iverach et al. (2010) reported (non-significant) odds ratios for substance 
dependence (OR = 0.50) that indicate AWS were approximately two (i.e., 1/.050) times less   
likely than AWNS to exhibit substance use disorder.  This pattern of frequency in medication use  
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contrasts with data from non-stuttering adults with anxiety disorders (Kessler, Chin, Demler, & 
Walters, 2005), or anxiety disorders secondary to other medical diagnosis such as multiple 
sclerosis (Patten, Beck, Williams, Barbui, & Metz, 2003) and epilepsy (Swinkels, Kuyk, 
deGraaf, van Dyck, & Spinhoven, 2001). The unexpected lower likelihood of substance use 
disorder reported by Iverach and colleagues (2010), and its inconsistency with well-established 
data from other clinical populations, warrant further investigation based on two critical 
limitations. 
 First, as noted by Iverach et al. (2010), the potential influence of sampling bias in AWS 
respondents may have impacted the reported outcomes.  AWS participants included in the study 
were selected from a waiting list for traditional clinical intervention and had initiated the 
treatment process at the time the survey was completed.  It is possible that AWS who have not 
actively sought treatment may be more likely to exhibit higher levels of stigmatization, and by 
extension, an increased likelihood (or history) of self-medication.   Non-stuttering adults who 
exhibit high levels of self-stigma have more negative attitudes toward seeking clinical services 
(e.g., Conner et al., 2010), and may be less willing to return for subsequent sessions after initial 
visit (e.g., Fung, Tsang, & Corrigan, 2008). Based on these associated patterns of substance use, 
stigma, and help-seeking in non-stuttering populations, AWS participants within Iverach et al. 
may not have provided the most representative sample of the broader stuttering population.   
 Second, diagnostic criteria for substance use disorder, as defined by the DSM-IV (2000) 
and implemented in Iverach et al. (2010), may have been too stringent to expose the overall 
frequency of medication use in AWS as compared to AWNS. The DSM-IV defines medication 
abuse as a maladaptive pattern of use and is manifested by three or more of the following within 
a 12-month period: (1) tolerance, as defined by the need for markedly increased amounts or 
diminished effects with continued use of the same amount, (2) physiological withdrawal 
symptoms, (3) substance taken longer than intended and in larger amounts, (4) persistent and/or 
unsuccessful attempts to reduce substance use, (5) excessive time dedicated to seeking or using 
substance, (6) participation in meaningful social, occupational, or recreational events are reduced 
or given up because of substance use, and/or (7) substance use is continued despite knowledge of 
addiction.  Given the rigor of the criteria, it is possible that medication use may be more 
prevalent in AWS than AWNS, without breaching the DSM-IV criteria for substance use 
disorder.  
 Longitudinal studies of substance use by McCabe and colleagues (2004; 2005; 2007; 
2011; 2014) utilize an alternative approach that can also be used to examine substance use 
frequency between AWS and AWNS. The College Student Life Survey (CSLS) (Johnston, 
O’Malley, Bachman, & Schulenberg, 2013, Substance Abuse Mental Health Services 
Administration [SAMSHA], 2009) examined trends in the lifetime and past-year prevalence of 
medical and nonmedical use of four prescription medication classes (i.e., sedative/anxiety, 
opioid, sleeping, and stimulant) of adults ages 17 to 56 (McCabe, West, Teter, & Boyd, 2014). 
Nonmedical use of prescription medications was assessed by the tool providing a brief definition 
of the terminology, and was followed by a question (e.g., “Sometimes people use prescription 
drugs that were meant for other people even when their own doctor has not prescribed it for 
them. On how many occasions (your lifetime or the past 12 months) have you used the drug type 
x not prescribed to you?”). Medical use of prescription medications was assessed in a similar 
manner (e.g., “Based on a doctor’s prescription, on how many occasions (in your lifetime or the 
past 12 months) have you used drug type x?”). In McCabe et al.’s (2014) study, other than  
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general demographics (e.g., race, age, highest level of education), no other criteria included in 
the DSM-IV were asked. This broader assessment of medication use, as opposed to reliance on 
diagnostic criteria, may offset potential under-estimation of medication use in AWS relative to 
AWNS. Thus, the CSLS may be a better metric to measure medication use, as opposed to 
medication abuse, and may reveal more pertinent differences between groups.   
 Based on these potential limitations of data reported by Iverach et al. (2010), the purpose 
of the present study is to strengthen the fidelity of their data by (a) broadening the AWS sample 
frame beyond clinical cohorts, (b) examining substance use, rather than substance use disorder, 
in AWS and AWNS, and (c) simultaneously assessing the influence of self-stigma in AWS 
respondents. To expand the AWS sample frame, respondents were taken from the National 
Stuttering Association (NSA) membership database. To assess patterns of medication use 
irrespective of criteria for physiological dependence, AWS and AWNS respondents completed 
the College Student Life Survey (CSLS) (Johnston et al., 2013, SAMSHA, 2009) used in McCabe 
et al. (2014).  To assess self-stigma, AWS participants completed the Self-Stigma Scale of 
Stuttering (4S) established by Boyle (2013).  It was predicted that AWS would report increased 
substance use relative to AWNS, and that medication use in AWS would correlate with increased 
levels of self-stigma.   Findings may provide a more precise picture of substance use differences 
in AWS relative to AWNS.  
 
In sum, the present study investigated two specific research questions:   
1) Does lifetime medication use in AWS differ from AWNS? 
2) Does lifetime medication use in AWS correlate with perceived level of self-stigma?  
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CHAPTER II: METHODS 
 
Participants 
Table 1.0 illustrates the sample distribution for adults who do not stutter (AWNS) and adults 
who stutter (AWS). For the present study, potential AWS participants were recruited from the 
membership roster of the National Stuttering Association (NSA) upon approval from the NSA 
Research Committee, with a target sample size of 100. Similar to McCabe et al. (2014), AWNS 
were sampled from a college in the southern United States region, also with a target sample size 
of 100. Specifically, respondent distribution was taken from the following information: (1) 
gender, (2) race (3) age, and (4) highest level of education. The racial/ethnic responses in 
distribution for the overall sample included White, Asian, African-American, Hispanic, and 
Other/not included/none. Age of respondents were reported in terms of mean ages. The options 
for highest education completed included: (1) did not complete high school, (2) graduated from 
high school, (3) completed some college, (4) completed undergraduate college degree, (5) 
complete some graduate coursework, (6) completed graduate degree.   
 
Table 1. Demographic characteristics for AWNS and AWS 
 
 AWNS AWS 
Number of respondents 105 215 
Gender   
   Male 8.4% 39.1% 
   Female 24.4% 28.1% 
Race   
   White 25.9% 49.7% 
   Asian 2.2% 4.7% 
   African-American 2.2% 5.3% 
   Hispanic 1.3% 4.1% 
   Other/not included/none 1.3% 3.4% 
Age 18-58 18-87 
Education   
   High school degree 8.3% 9.2% 
   Undergraduate college degree 19.4% 31.7% 
   Graduate degree 5.7% 25.7% 
 
Measures 
College Student Life Survey (CSLS; Johnson et al., 2013). The CSLS is a self-report 
medication survey that measures medication use such as stimulants and sleeping medications. 
There is a general consensus that self-report surveys have a high degree of validity, as long as the 
survey is a self-administered on the computer (McCabe et al., 2014), and the participant is aware 
that responses will remain anonymous. The CSLS included the following items: “How many 
occasions (in your lifetime or the past 12 months) have you used the following types of 
medications?” A separate question was presented for each of the four classes of prescription 
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medications: (a) sleeping medication (e.g., Ambien, Halcion, Restoril, temazepam, triazolam); 
(b) sedative/anxiety medication (e.g., Ativan, Xanax, Valium, Klonopin, diazepam, lorazepam); 
(c) stimulant medication (e.g., Ritalin, Dexedrine, Adderall, Concerta, methlyphenidate); and (d) 
pain medication (i.e., opioids such as Vicodin, OxyContin, Tylenol 3 with codeine, Percocet, 
Darvocet, morphine, hydrocodone, oxycodone). The response scale for each question ranged 
from (1) no occasions to (7) 40 or more occasions.  
Self-Stigma Scale of Stuttering (4S; Boyle, 2013). The Self-Stigma Scale of Stuttering (4S) 
included the following items: “How severe overall (over your lifetime) do you find your 
stuttering to be?”, “How severe do you find your stuttering to be over the last week?”,  “Most 
people in the general public believe that people who stutter are x”, “When talking to a person 
who stutters, most people in the general public feel x”, “Most people in the general public 
believe that people who stutter should x”, “I believe that people who stutter are generally x”, 
“Because I stutter, I feel x”, and “Because I stutter, I stop myself from x”.  
 
Procedures 
The College Student Life Survey (CSLS) (Johnston et al., 2013, SAMSHA, 2009) and the 
Self-Stigma Scale of Stuttering (4S) (Boyle, 2013) was administered to participants in the form of 
a combined survey entitled “Medication Use Questionnaire” via Qualtrics Survey Software. The 
study was conducted during a three-month period.  The sample was sent a pre-notification letter 
including the description of the study, option to opt-out, and request of informed consent for 
participation in the study. If participants agreed to participate, each were self-administered the 
"Medication Use Questionnaire" survey. To ensure privacy and security, no identifying 
information was collected as part of the survey, and all IP addresses were compiled and stored on 
a password protected server. Only the director and approved research assistants had access to 
individual IP addresses.  Respondents completed one online 24-question survey, taking about 15-
20 minutes to complete. An identical pilot survey was used to identify unclear questions before 
beginning the study.  
The survey request email included a description of the study, information regarding 
confidentiality of responses, the study’s IRB reference number, and informed consent. 
Respondents were free to terminate survey participation during or after completion. The survey 
included the following sections: (1) demographic information (e.g., gender, race, education), (2) 
lifetime medication use (CSLS; Johnston et al., 2013, SAMSHA, 2009) via a Likert scale, (3) 
past-year medication use (Johnston et al., 2013, SAMSHA, 2009) via Likert scale, (4) stuttering 
history (e.g., treatment history, stuttering severity over the past week), and if the respondent self-
identified as an AWS, (5) the Self-stigma of Stuttering (4S; Boyle, 2013).  See Appendix A for 
the entire survey and informed consent form.  
      Sampling procedure. There were 320 adults (105 AWNS, 215 AWS) included in the study 
and recruited via two separate methods.  To target AWS respondents, announcements of the 
survey were sent to the entire membership roster of the National Stuttering Association (NSA) 
via email. Membership roster for the NSA included an estimated 14,334 unique email addresses 
with permission of the National Stuttering Association Research Committee.  Three email 
notifications were sent out between the months of January 2017 and February 2017.  Of the  
14,334 potential respondents, 14,122 (98.5%) did not respond, 17 (.12%) did not complete, zero 
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opted-out, and zero bounced back due to email settings, resulting in a total of 195 (1.36%) 
complete responses from the NSA participant pool. Of these 195 respondents, two respondents 
identified as AWNS, and the remaining 193 respondents identified as AWS. 
The control group consisted of 105 AWNS in the study. In order to target AWNS 
respondents, announcements of the survey were sent to 2,000 students randomly selected by the 
Office of the University Registrar at Louisiana State University. All 2,000 potential respondents 
were notified of the survey via email. Three notifications were sent out between December 2016 
and February 2017. Of the 2,000 potential respondents, 1,844 (92.2%) did not respond, 27 
(1.35%) did not complete, zero opted-out, and four (0.20%) bounced back due to email settings, 
resulting in a total of 125 (6.25%) complete responses from the AWNS participant pool.  Of 
these 125 respondents, 22 identified as AWS, and the remaining 103 respondents identified as 
AWNS.   In sum, a total of 105 AWNS and 215 AWS completed the survey and were included 
in the present study.  
 
Reliability  
 To assess the fidelity of the survey, one round of piloting was completed by five research 
assistants, as well as 10 first-year graduate students within the university’s department of 
communication disorders.  Any necessary clarifications or modification were made before wide 
distribution.  Full return surveys were coded by the primary author and the faculty supervisor.  
Inter- and intra-rater reliability were assessed using Kappa coefficients and percent agreement 
between and within raters.  Responses were coded with 100% accuracy and perfect correlation 
(Kappa = 1.00). 
 
Analysis  
All analyses were conducted using the IBM SPSS Statistics Software (version 23).  A 
binary logistic regression model was conducted, with lifetime use of medication as the binary 
dependent variable, and talker groups serving as an independent variable (AWNS, AWS).  Age, 
gender, education, and race/ethnicity were included as covariates based on the well-established 
relationship between these four factors and medication use (McCabe et al., 2014; Johnston & 
O'Malley, 1985).  Based on the limitations of the Iverach et al. (2010) study, it was predicted that 
AWS not restricted to clinical waitlist will report higher likelihood of medication use relative to 
AWNS.  Results of regression analyses were described in terms of odds ratio (OR) and 95% 
confidence intervals (CI). 
A second binary logistic regression was conducted to examine the relationship between 
self-stigma related to stuttering within the AWS cohort (n = 215), with lifetime use of medication 
as the binary dependent variable and Total Stigma Score derived from responses on the 4S and 
described by Boyle (2015) as the predictor variable.  Based on previous studies that indicate a 
relationship between self-stigma and medication use, it was also predicted that higher frequency 
of medication use for AWS would be positively correlated with higher levels of self-stigma.  
Similar to measurement of overall use between groups, the four predetermined factors of age, 
gender, education, and race/ethnicity were controlled for during analysis. 
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CHAPTER III: RESULTS 
 
Lifetime medication use in AWS versus AWNS   
While controlling for the effects of age, gender, education, and race/ethnicity, self-identification 
as an adult who stutters was not as a significant predictor of medication use (OR = 0.809, CI = 
0.444-1.471, p = .487).  Similar to Iverach et al. (201), a non-significant trend was detected that 
suggests the odds or likelihood of medication use during their lifetime was 1.91 times lower for 
individuals who self-identified as AWS compared to AWNS. 
 
Medication use and self-stigma in AWS   
While controlling for the effects of age, gender, education, and race/ethnicity, increased self-
stigma as measured by Total Stigma Score was as a significant predictor of medication use (OR 
= 1.918; CI = 1.005-3.658, p = .048).  That is, as self-stigma scores for AWS increased on the 
Total Stigma Scale by one point (i.e., became more negative), the odds or likelihood medication 
use during their lifetime were 1.92 times greater.  See Table 2.0 for detailed breakdown of 
medication use reported by AWS and AWNS. 
 
Table 2. Lifetime medication use reported by AWNS and AWS 
 AWNS (n = 105) AWS (n = 215) All Respondents 
Lifetime use    
     Sleeping medication 30.5% 28.4% 29.1% 
     Sedative/anxiety medication 35.2% 33.0% 33.8% 
     Stimulant medication  27.6% 20.5% 22.8% 
     Pain medication 54.3% 39.5% 44.4% 
     Other medication 13.3% 20.0% 17.8% 
     Any medication 61.0% 58.1% 59.1% 
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CHAPTER IV: DISCUSSION 
  
 The purpose of this study was to re-examine the frequency of medication use in AWS 
relative to AWNS reported by Iverach et al. (2010) based on two potential limitations.  First, the 
measure used by Iverach et al. (2010) to compare groups relied on criteria for substance abuse as 
defined by the DSM-IV (2000), and were perhaps too stringent to detect non-clinical differences 
in medication use, rather than abuse, between groups.  To address this issue, the present study 
assessed medication use without regard to clinical criteria.  It was predicted that AWS may 
demonstrate increased medication use relative to AWNS without meeting criteria for formal 
diagnosis of substance abuse.   
Second, the Iverach et al. (2010) sample was drawn from a clinical waitlist, which may have 
captured medication use patterns of AWS that were more willing to openly address stuttering, 
and perhaps less prone to self-medicate.  Highly stigmatized populations such as stuttering have 
been found to correlate with increased medication use (e.g., Lai et al., 2015) and report more 
negative attitudes towards initiating treatment (e.g., Conner et al., 2010).  To address this issue, 
the present study (a) sampled AWS from non-clinical cohort via a nationwide database, and (b) 
estimated the relationship between medication use and self-stigma within the AWS cohort.  It 
was predicted that higher levels of self-stigma may be significantly correlated with medication 
use within the AWS cohort. 
In sum, the present study adopted modified methodology to re-examine research question 
originally posed by Iverach et al. (2010).  Based on the two noted limitations, this study 
investigated lifetime medication use in AWS relative to AWNS irrespective of DSM-IV criteria, 
and to what extent self-stigma may contribute to medication use in AWS. The following two 
specific research questions were posed: 
1) Does lifetime medication use in AWS differ from AWNS? 
2) Does lifetime medication use in AWS correlate with perceived level of self-stigma? 
Results from the present study indicated that, similar to Iverach et al. (2010), the likelihood 
of lifetime medication use was not significantly higher for AWS compared to AWNS and, in 
fact, replicated the non-significant trend toward reduced medication use in AWS.  However, of 
the AWS who completed the survey, the likelihood of medication use within their lifetime 
significantly increased as self-reported self-stigmatization increased.   These findings suggest 
that cognitive and affective aspects of stuttering may mitigate medication use in AWS more so 
than the mere presence of a fluency disorder.    
 
Medication Use in AWS Versus AWNS 
 Based on increased rates of anxiety in AWS reported by Iverach et al. (2009), and the two 
limitations noted within Iverach et al. (2010), it was predicted that AWS as a group would 
exhibit a greater likelihood of lifetime medication use than AWNS upon removal of DSM-IV 
criteria as an outcome measure.  However, despite this modification, AWS were no more likely 
to report medication use within their lifetime than AWNS.  These findings are inconsistent with 
our predictions but consistent with Iverach et al. (2010), and similarly, also indicate a non-
significant negative likelihood of medication use in AWS.  Combined, these findings provide an 
optimistic account of medication use trends by AWS and further suggest that medication use  
 
10 
 
 
within this population may be delimited by internal attitudes towards stuttering rather than the 
diagnostic label itself. 
 The proportion of AWS that reported medication use in the present study nearly doubled 
(58.1%, see Table 2.0) the proportion of AWS respondents identified by the NSA (2009) to have 
tried alternative methods of treatment -- such as medication -- to address fluency concerns.  A 
few cautions are warranted when comparing between these studies.  First, the number of AWS 
respondents in the NSA report (n = 711) were over three times larger than the present study (n = 
215).  Second, medication use was considered one of several alternative methods of treatment by 
NSA (2009; e.g., hypnosis, herbal remedy, motivational course), and therefore the specific 
number of respondents that used medication in the 2009 study cannot be determined.  Third, only 
46 of the 125 AWS who reported medication use in the present study also indicated that 
medication was taken specifically to address speech fluency.  By this estimate, the number of 
respondents in the present study who consumed medication solely for the purposes of alleviating 
stuttering (21.4%) were more comparable to the 2009 NSA report.  This consistency across 
surveys provides a valuable estimate regarding the prevalence of medication use in AWS taken 
specifically for symptoms related to stuttered speech (approximately 20% to 30%), even if 
overall use (58.1%) was similar to typically fluent adults in this study (61.0%), and within the 
broader population over the past 15 years (52.4% - 57.5%; McCabe et al., 2014).  
The present findings are not without limitations and should be considered preliminary in 
nature.  Response rate was low within each group (AWS = 1.6%, AWNS = 6.25%), and the 
number of AWNS respondents (n = 105) fewer than half of the total AWS respondents (n = 215).  
Response bias was a likely contributing factor to the disproportionate response rate between 
groups.  Individuals who stutter, and perhaps individuals who use medication, may be more 
willing to complete the survey than a non-stuttering, non-medicated adults.  Another potential 
factor which may have contributed to response bias is the reticence of respondents (AWS and 
AWNS) to willingly report medication use, in particular non-prescription use, during an online 
survey regardless of the safeguards provided to protect anonymity.  In addition, sampling 
potential AWNS from a single university may have provided an atypical profile compared to 
AWS due to restricted age and geographic distribution.  Future follow-up studies should sample 
AWNS respondents from a broader database with national distribution to more adequately 
compare between groups. Finally, and similar to Iverach et al. (2010), estimation of medication 
use in the present study did not directly address whether specific medications were taken for 
diagnoses that were unrelated to fluency disorders versus diagnoses that co-occur secondary to 
fluency disorders.  As noted in the introduction, AWS may also exhibit heightened levels of 
anxiety, social phobia, or depression (Iverach et al., 2009; 2010), which may in turn increase the 
likelihood of pharmaceutical intervention.  The second purpose of this study provides some 
insight into this final limitation by examining to what extent self-stigmatization – a measurement 
correlated with reported levels of anxiety, social phobia, and depression - may influence use of 
medication by AWS during their lifetime. 
 
Medication Use and Self-stigma in AWS   
 Based on the potential for elevated negative self-perception in AWS, and the relationship 
between self-stigmatization and self-medication, it was predicted that medication use in AWS 
would be significantly associated with reported levels of self-stigma.  Results from the Self- 
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Stigma Scale of Stuttering (4S) (Boyle, 2013) revealed that Total Stigma Score was indeed a 
significant predictor of medication use. Boyle (2015) reported that higher scores on the Total 
Stigma Score are significantly associated increased anxiety and depression, and decreased 
quality-of-life, hope, and empowerment. It is perhaps unsurprising, then, that as AWS scores on 
Total Stigma Scale increased by one (on a scale of five), AWS were nearly twice as likely (OR = 
1.92) to report medication use.  Again, it is important to acknowledge the comparable overall 
medication use between AWS and AWNS, which suggests that AWS as a group were not 
predisposed to increased substance use.  Combined data indicate, instead, that increased 
medication use may occur as an individual AWS adopts increasingly negative beliefs about their 
experiences as a person who stutters. 
 Findings are also consistent with stigmatized populations within the field of mental 
health.  For example, Robinson et al. (2011) found that populations with clinical anxiety 
disorders also reported greater levels of self-stigma, and are more likely to self-medicate.  It 
should be noted that the average mean score on the Total Stigma Scale was statistically different 
but descriptively similar between AWS who did not report medication use (M = 3.24, SE = .05) 
and those who had (M = 3.31, SE = .04).  Additional factors not included in this study 
undoubtedly contributed to the respondents’ choice to take medication.  That said, only one of 
the six AWS who scored between lower than 2.5 (lower levels of self-stigma) reported 
medication use during their lifetime, whereas 45 of the 65 AWS who scored above 3.5 (neutral 
or high self-stigma, n = 65) reported medication use during their lifetime.  Thus, a shift from 
negative or even neutral self-perception to more overtly positive self-perception over the course 
of treatment for may correspond with lower likelihood to initiate medication for AWS.  In a 
similar vein, AWS clients who enter treatment with scores that are more notably negative may be 
more likely to currently take medications.  This pattern may also warrant further investigation 
with regard to potential risk factors of long-term medication use in AWS.  Future research is 
necessary to confirm whether this is the case. 
 Admittedly, assessing medication use in a binary fashion (i.e., any use of any medication 
across a lifetime) is a broad metric.  The decision to include all medications in to one category 
irrespective of type or dosage was intentional, as all types of medications included in this study 
(i.e., sedatives or “antianxiety” medications, and stimulants or “antidepressant” medications) 
have received some empirical attention with the exception of sleeping medications (see Saxon & 
Ludlow, 2007).  As illustrated in Table 2.0, all medication types were used with similar 
frequency in AWS and AWNS.  An interesting pattern was the increased proportion of AWNS 
(57 or 105, or 54.3%) compared to AWS (85 or 215, or 39.5%) who reported taking pain 
medication, described as “opioids, Vicodin, OxyContin, codeine, Percocet, Darvocet, morphine, 
hydrocodone, or oxycodone.”  Of these 57 AWNS respondents who reported taking pain 
medication, 14 AWNS (24.6%) reported doing so without formal medication (higher than 8.8% 
nonmedical use of pain medication reported for college students by McCabe et al., 2014).  In 
contrast, a greater percentage of AWS (43 of 85, or 50.5%) took pain medication with no formal 
prescription.  Of these 43 AWS, almost half (19, or 44.18) took pain medication alone or in 
combination with other medications specifically to address symptoms related to stuttered speech.  
It should be cautioned that these response patterns are preliminary and a broader AWNS 
database should be compiled to accurately appraise the data at this level.  Follow-up 
investigation is warranted to further examine the potential underlying reasons for this unique 
association between opioid-class medications and individuals who stutter.   
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Finally, the present study was designed for the specific purpose of evaluating medication 
use in AWS compared to AWNS, and the relationship between medication use and self-stigma.  
There is certainly additional information that can be gleaned from this data set, including the 
distribution of specific medication types, the potential impact of socio-economic factors on 
medication use, patterns of use with regard to dosage and prescription versus non-prescription 
medication, the relationship stuttering severity and medication use, and the potential relationship 
between subscales of the 4S scale (awareness, agreement, and application).  The data collected 
may provide preliminary insight into these topics in future studies, but the scope of the study was 
restricted to these topics to capture a broad picture of medication use in AWS relative to AWNS, 
and the potential relationship between broad psychosocial profiles specific to a lifetime of 
stuttering and the likelihood of medication use in AWS. 
  
Conclusion 
The purpose of the present study was to investigate differences in medication use 
between AWS and AWNS and to examine whether a relationship among their self-stigma and 
medication use is present in AWS.   Results suggest that although there is not a significant 
difference for lifetime medication use between AWS versus AWNS, the self-imposed stigma by 
AWS could predict the likelihood of medication use.  Findings provide insight into additional 
pharmacological factors to consider during clinical intervention, and highlight the importance of 
stigmatized beliefs when addressing the needs of a client who stutters. 
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